Beta-blocker therapy after acute coronary syndrome in patients without heart failure or reduced ejection fraction: a target-trial emulation study

European Journal of Preventive Cardiology 2026

View at publisher
Authors: Vincenzo De Sio, Felice Gragnano, Arturo Cesaro, M Galli, Elisabetta Moscarella, Martina Berteotti, Antonio Capolongo, Francesco Pelliccia, G Verde, Pierre François Sabouret, Vincenzo Acerbo, M Luciani
+11 more G Cappiello, Dobromir Dobrev, Francesco Perone, Giuseppe Patti, E Antonucci, Pasquale Pignatelli, Vittorio Pengo, Paolo Gresele, Plinio Lorenzo Cirillo, Rossella Marcucci, Paolo Calabrò
DOI: 10.1093/eurjpc/zwag381
Cited by: 1
References: 39

Abstract

AIMS: The benefits of β-blockers in patients with acute coronary syndromes (ACS) without chronic heart failure (HF) or left ventricular ejection fraction (LVEF) < 40% remain uncertain. We evaluated the association between β-blocker therapy and clinical outcomes in a multicenter, contemporary ACS registry. METHODS: In the START-ANTIPLATELET registry (NCT02219984), patients were excluded if they had HF or LVEF

Fields of Study & Subjects

Acute Myocardial Infarction Research Heart Failure Treatment and Management Cardiac Anesthesia and Surgical Outcomes

Publication details

Journal / source
European Journal of Preventive Cardiology
Publisher
Oxford University Press (OUP)
Publication date
21 July 2026
Language
EN